Patent · US Active

1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

US7576109B2 · kind B2 · utility

0Cited by

4References

15Claims

0Family size

Assignees

Aventis Pharmaceuticals Inc. · US
Sanofi-Aventis Deutschland GMBH · DE

Inventors

Daniel McGarry · King of Prussia, US
Karen Chandross · Somerville, US
Jean Merrill · Morristown, US
Jochen Goerlitzer · Frankfurt am Main, DE
Stefanie Keil · Frankfurt am Main, DE
Wolfgang Wendler · Bad Camberg, DE
Patrick Bernardelli · Fontenay-aux-Roses, FR

Key dates

Filing date	Sep 26, 2006
Grant date	Aug 18, 2009
Priority date	—
Expiry date	Aug 11, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.